Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2008-07-03
2010-10-26
Lucas, Zachariah (Department: 1648)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S387100, C530S388260, C435S338000, C435S346000
Reexamination Certificate
active
07820797
ABSTRACT:
A glycolipopeptide comprising a carbohydrate component, a peptide component and a lipid component, for use as a therapeutic or prophylactic vaccine. Also provided are monoclonal and polyclonal antibodies that recognize the glycolipopeptide of the invention, as well as uses thereof.
REFERENCES:
patent: 5503829 (1996-04-01), Ladant et al.
patent: 5679784 (1997-10-01), Ladant et al.
patent: 5876949 (1999-03-01), Dreyfuss et al.
patent: 5935580 (1999-08-01), Ladant et al.
patent: 6258796 (2001-07-01), Richards
patent: 6413935 (2002-07-01), Sette et al.
patent: 6544952 (2003-04-01), Danishefsky et al.
patent: 6645935 (2003-11-01), Danishefsky et al.
patent: 6676946 (2004-01-01), Bay et al.
patent: 2002/0038017 (2002-03-01), Danishefsky et al.
patent: 2002/0055121 (2002-05-01), Vielkind
patent: 2003/0157115 (2003-08-01), Bay et al.
patent: 2006/0069238 (2006-03-01), Koganty et al.
patent: 2007/0160622 (2007-07-01), Turnell et al.
patent: 2009/0196916 (2009-08-01), Ingale et al.
patent: WO 95/07707 (1995-03-01), None
patent: WO 98/43677 (1998-10-01), None
patent: WO 00/12536 (2000-03-01), None
patent: WO 00/12536 (2000-06-01), None
patent: WO 02/43699 (2002-06-01), None
patent: WO 02/043699 (2002-10-01), None
patent: WO 03/089574 (2003-10-01), None
patent: WO 03/089574 (2003-10-01), None
patent: WO 03/089574 (2003-10-01), None
patent: WO 2007/067744 (2007-06-01), None
patent: WO 2007/146070 (2007-12-01), None
patent: WO 2007/146070 (2008-04-01), None
patent: WO 2007/067744 (2009-09-01), None
Buskas et al., “Towards a Fully Synthetic Carbohydrate-Based Anticancer Vaccine: Synthesis and Immunological Evaluation of a Lipidated Glycopeptide Containing the Tumor-Associated Tn Antigen,” Angwandte Chemie, vol. 117, pp. 6139-6142 (online Aug. 2005).
Comer et al., “Characterization of a Mouse Monoclonal Antibody Specific for O-Linked N-Acetylglucosamine,” Analytical Biochemistry, vol. 293 No. 2, pp. 169-177 (Jun. 2001).
Devine et al., “The Breast Tumor-associated Epitope Defined by Monoclonal Antibody 3E1.2 Is an O-linked Mucin Carbohydrate Containing N-GlycolylneuraminicAcid,” Cancer Research, vol. 5, pp. 5826-5836 (Nov. 1991).
Dudkin et al., “Toward Fully Synthetic Carbohydrate-Based HIV Antigen Design: On the Critical Role of Bivalency,” Journal of the Americal Chemical Society, vol. 126, pp. 9560-9562 (ePub Jul. 2004).
Nozawa et al., “HMMC-1: A Humanized Monoclonal Antibody With Therapeutic Potential Against Mu{umlaut over ())}{umlaut over (})} Ilerian Duct-Related Carcinomas,” Clinical Cancer Research, vol. 10, pp. 7071-7078 (Oct. 2004).
Reichel et al., “Synthetic carbohydrate-based vaccines: synthesis of an L-glycero-D-manno-heptose antigen—T-epitope—lipopeptide conjugate,” Chemical Communications, vol. 21, pp. 2087-2088 (1997).
van Kuppevelt et al., “Generation and Application of Type-specific Anti-Heparan Sulfate Antibodies Using Phage Display Technology,” Journal of Biological Chemistry, vol. 273 No. 21, pp. 12960-12966 (May 1998).
Ada and Issacs, “Carbohydrate-protein conjugate vaccines,” Feb. 2003Clin. Microbiol. Inf. 9(2):79-85.
Adluri et al., “Immunogenicity of synthetic TF-KLH (keyhole limpet hemocyanin) and sTn-KLH conjugates in colorectal carcinoma patients,” Sep. 1995Cancer Immunol. Immunother. 41(3):185-192.
Akintonwa, “Theoretical mechanistic basis of the toxic effects and efficacy of dideoxycytidine in HIV:AIDS,” Aug. 2001Medical Hypotheses57(2):249-251.
Akira et al., “Toll-like receptors: critical proteins linking innate and acquired immunity,” Aug. 2001Nat. Immunol. 2(8):675-680.
Akira and Takeda, “Toll-like receptor signalling,” Jul. 2004Nat. Rev. Immunol. 4(7):499-511.
Alexander et al., “Development of high potency universal DR-restricted helper epitopes by modification of high affinity DR-blocking peptides,” Dec. 1994Immunity1(9):751-761.
Alexander et al., “Linear PADRE T helper epitope and carbohydrate B cell epitope conjugates induce specific high titer IgG antibody responses,” Feb. 1, 2000J. Immunol. 164(3):1625-1633.
Alexandrov et al., “Intein-mediated synthesis of geranylgeranylated Rab7 protein in vitro,” May 22, 2002J. Am. Chem. Soc. 124(20):5648-5649. Available online on Apr. 27, 2002.
Aliprantis et al., “Cell activation and apoptosis by bacterial lipoproteins through toll-like receptor-2,” Jul. 30, 1999Science285(5428):736-739.
Anderson et al., “Effects of oligosaccharide chain length, exposed terminal group, and hapten loading on the antibody response of human adults and infants to vaccines consisting ofHaemophilus influenzaetype B capsular antigen unterminally coupled to the diphtheria protein CRM197,” Apr. 1, 1989J. Immunol. 142(7):2464-2468.
Apostolopoulos et al., “MUC1 and breast cancer,” Feb. 1999Curr. Opin. Mol. Ther. 1(1):98-103.
Ausubel et al. (eds.),Current Protocols in Molecular Biology, vols. 1-4, John Wiley & Sons, Inc., New York, NY, 1992-1996; title page, publisher's page and table of contents only (26 pages).
Baldus et al., “MUC1 and the MUCs: a family of human mucins with impact in cancer biology,” 2004Crit. Rev. Clin. Lab. Sci. 41(2):189-231.
Barber et al., “Possible mechanisms of mammalian immunocontraception,” Mar. 2000J. Reprod. Immunol. 46(2):103-124.
Barchi, Jr., “Emerging roles of carbohydrates and glycomimetics in anticancer drug design,” Mar. 2000Current Pharmaceutical Design6(4):485-501.
Berzofsky et al., “Strategies for designing and optimizing new generation vaccines,” Dec. 2001Nat. Rev. Immunol. 1(3):209-219.
Beutler, “Innate immunity: an overview,” Feb. 2004Mol. Immunol. 40(12):845-859.
Bevan, “Helping the CD8+ T-cell response,” Aug. 2004Nat. Rev. Immunol. 4(8):595-602.
Blander and Medzhitov, “Toll-dependent selection of microbial antigens for presentation by dendritic cells,” Apr. 6, 2006Nature440(7085):808-812. Available online on Feb. 19, 2006.
Boons, Geert-Jan, “Synthesis/Immunological Properties of Lewis Antigens,” Grant Abstract, Grant No. 1RO1CA088986-01A2 [online]. National Cancer Institute, National Institutes of Health; project dates Jul. 15, 2002 to Jun. 30, 2006 [retrieved on Jan. 6, 2009]. Retrieved from the Internet: <http://crisp.cit.nih.gov/crisp/CRISP—LIB.getdoc?textkey=6546986&p—grant—num=1R01CA088986-01A2&p—query=&ticket=84444686&p—audit—session—id=393574951&p—keywords=>; 2 pgs.
Boons, Geert-Jan, “Synthesis/Immunological Properties of Lewis Antigens,” Grant Abstract, Grant No. 5RO1CA088986-02 [online]. National Cancer Institute, National Institutes of Health; project dates Jul. 15, 2003 to Jun. 30, 2006 [retrieved on Jan. 6, 2009]. Retrieved from the Internet: <http://crisp.cit.nih.gov/crisp/CRISP—LIB.getdoc?textkey=6605801&p—grant num=5R01CA088986-02&p—query=&ticket=84444686&p—audit—session—id=393574931&p—key words=>; 2 pgs.
Boons, Geert-Jan, “Synthesis/Immunological Properties of Lewis Antigens,” Grant Abstract, Grant No. 5RO1CA088986-03 [online]. National Cancer Institute, National Institutes of Health; project dates Jul. 15, 2002 to Jun. 30, 2006 [retrieved on 2009-01-06]. Retrieved from the Internet: <http://crisp.citnih.gov/crisp/CRISP—LIB.getdoc?textkey=6752388&p—grant—num=5R01CA088986-03&p—query=&ticket=84444686&p—audit—session—id=393574951&p—key words=>; 2 pgs.
Boons, Geert-Jan, “Synthesis/Immunological Properties of Lewis Antigens,” Grant Abstract, Grant No. 5RO1CA088986-04 [online]. National Cancer Institute, National Institutes of Health; project dates Jul. 15, 2002 to Nov. 30, 2006 [retrieved on Jan. 6, 2009]. Retrieve
Lucas Zachariah
Mueting Raasch & Gebhardt, P.A.
University of Georgia Research Foundation Inc.
LandOfFree
Glycolipopeptide antibodies does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Glycolipopeptide antibodies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Glycolipopeptide antibodies will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4237800